Susceptibility testing of unconventional antibiotics against multiresistant Acinetobacter spp. by agar dilution and Vitek 2

Diagnostic Microbiology and Infectious Disease

Volumn 58, Issue 3, 2007, Pages 357-361

  Tan, Thean Yen ^a   Ng, Lily Siew Yong ^a   Poh, Karen ^a  

^a CHANGI GENERAL HOSPITAL   (Singapore)

Author keywords

Acinetobacter baumannii; Colistin; Rifampicin; Susceptibility tests; Tetracycline; Vitek

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEFTAZIDIME; CEPHALOSPORIN; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; MINOCYCLINE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULTAMICILLIN; TETRACYCLINE;

ACINETOBACTER; ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STRAIN DIFFERENCE;

ACINETOBACTER; ANTI-BACTERIAL AGENTS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; RIFAMPIN;

EID: 34347331060     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2007.02.008     Document Type: Article

References (25)

1. Afzal-Shah M., and Livermore D.M. Worldwide emergence of carbapenem-resistant Acinetobacter spp. J. Antimicrob. Chemother. 41 (1998) 576-577
2. Bergogne-Berezin E., and Towner K.J. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin. Microbiol. Rev. 9 (1996) 148-165
3. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. NCCLS Document M100-S15, Fifteenth Informational Supplement (2005), Clinical and Laboratory Standards Institute, Wayne
4. Clinical and Laboratory Standards Institute (CLSI). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Approved Standard M7-A7 (2006), Clinical and Laboratory Standards Institute, Wayne
5. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Supplement M100-S16 (2006), Clinical and Laboratory Standards Institute, Wayne
6. Falagas M.E., Fragoulis K.N., Kasiakou S.K., Sermaidis G.J., and Michalopoulos A. Nephrotoxicity of intravenous colistin: a prospective evaluation. Int. J. Antimicrob. Agents 26 (2005) 504-507
7. Garnacho-Montero J., Ortiz-Leyba C., Jimenez-Jimenez F.J., Barrero-Almodovar A.E., Garcia-Garmendia J.L., Bernabeu-Wittel I.M., Gallego-Lara S.L., and Madrazo-Osuna J. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin. Infect. Dis. 36 (2003) 1111-1118
8. Gerner-Smidt P., Tjernberg I., and Ursing J. Reliability of phenotypic tests for identification of Acinetobacter species. J. Clin. Microbiol. 29 (1991) 277-282
9. Gleeson T., Petersen K., and Mascola J. Successful treatment of Acinetobacter meningitis with meropenem and rifampicin. J. Antimicrob. Chemother. 56 (2005) 602-603
10. Grundmann H.J., Towner K.J., Dijkshoorn L., Gerner-Smidt P., Maher M., Seifert H., and Vaneechoutte M. Multicenter study using standardized protocols and reagents for evaluation of reproducibility of PCR-based fingerprinting of Acinetobacter spp. J. Clin. Microbiol. 35 (1997) 3071-3077
11. Henwood C.J., Gatward T., Warner M., James D., Stockdale M.W., Spence R.P., Towner K.J., Livermore D.M., and Woodford N. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J. Antimicrob. Chemother. 49 (2002) 479-487
12. Joyanes P., del Carmen Conejo M., Martinez-Martinez L., and Perea E.J. Evaluation of the VITEK 2 system for the identification and susceptibility testing of three species of nonfermenting gram-negative rods frequently isolated from clinical samples. J. Clin. Microbiol. 39 (2001) 3247-3253
13. Ling T.K., Tam P.C., Liu Z.K., and Cheng A.F. Evaluation of VITEK 2 rapid identification and susceptibility testing system against gram-negative clinical isolates. J. Clin. Microbiol. 39 (2001) 2964-2966
14. Obana Y., Nishino T., and Tanino T. In-vitro and in-vivo activities of antimicrobial agents against Acinetobacter calcoaceticus. J. Antimicrob. Chemother. 15 (1985) 441-448
15. Paterson D.L. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin. Infect. Dis. 43 Suppl 2 (2006) S43-S48
16. Petrosillo N., Chinello P., Proietti M.F., Cecchini L., Masala M., Franchi C., Venditti M., Esposito S., and Nicastri E. Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events. Clin. Microbiol. Infect. 11 (2005) 682-683
17. Saballs M., Pujol M., Tubau F., Pena C., Montero A., Dominguez M.A., Gudiol F., and Ariza J. Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections. J. Antimicrob. Chemother. 58 (2006) 697-700
18. Sader H.S., Fritsche T.R., and Jones R.N. Accuracy of three automated systems (MicroScan WalkAway, VITEK, and VITEK 2) for susceptibility testing of Pseudomonas aeruginosa against five broad-spectrum beta-lactam agents. J. Clin. Microbiol. 44 (2006) 1101-1104
19. Schreckenberger P.C., Daneshvar M.I., Weyant R.S., and Hollis D.G. Acinetobacter, Achromobacter, Chryseobacterium, Moraxella, and other nonfermentative gram-negative rods. In: Murray P.R., Baron E.J., Jorgensen J.H., Pfaller M.A., and Yolken R.H. (Eds). Manual of clinical microbiology (2003), ASM Press, Washington (DC) 749-779
20. Tan T.Y., and Ng L.S. Comparison of three standardized disc susceptibility testing methods for colistin. J. Antimicrob. Chemother. 58 (2006) 864-867
21. Tenover F.C., Weigel L.M., Appelbaum P.C., McDougal L.K., Chaitram J., McAllister S., Clark N., Killgore G., O'Hara C.M., Jevitt L., Patel J.B., and Bozdogan B. Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob. Agents Chemother. 48 (2004) 275-280
22. Timurkaynak F., Can F., Azap O.K., Demirbilek M., Arslan H., and Karaman S.O. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int. J. Antimicrob. Agents 27 (2006) 224-228
23. Van de Peer Y., and De Wachter R. TREECON for Windows: a software package for the construction and drawing of evolutionary trees for the Microsoft Windows environment. Comput. Appl. Biosci. 10 (1994) 569-570
24. Wareham D.W., and Bean D.C. In-vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases. Ann. Clin. Microbiol. Antimicrob. 5 (2006) 10
25. Wood G.C., Hanes S.D., Boucher B.A., Croce M.A., and Fabian T.C. Tetracyclines for treating multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia. Intensive Care Med. 29 (2003) 2072-2076